Here on the Refinery29 Most Wanted team, we’re all about shining a light on BIPOC-owned brands that deserve more love and recognition. To celebrate Asian American and Pacific Islander Heritage Month, we have given shoutouts to our favorite AAPI-owned fashion brands, as well as emerging Asian-owned beauty brands that should be on your shopping radar. There are also plenty of AAPI-owned home brands to support now (and all the time). Now, we’re highlighting the AAPI-owned lifestyle brands available on what is perhaps the most convenient shopping hub of them all — Amazon.

Alpine team principal Otmar Szafnauer will leave the team after this weekend’s Belgian Grand Prix in a shock announcement. Szafnauer joined the French team from Aston Martin at the start of last season but has seen his former team and McLaren leapfrog Alpine in the standings at the halfway stage of the 2023 campaign. Sporting director Alan Permane, who has been associated with Renault - the parent company of the Alpine brand - for 34 years, will also depart. An Alpine statement read: “The team would like to thank Otmar for his hard work over the past 18 months and for leading the team in achieving fourth place in the 2022 Constructors’ Championship. The team wishes him the best for the future. “After 34 distinguished years at Enstone, the team extends its thanks to Alan and wishes him the best in his future endeavours.” Bruno Famin, currently vice-president of Alpine Motorsports, will take up the role of interim team principal after the summer break from the Dutch Grand Prix onwards. Current academy director Julian Rouse will take the role of interim sporting director. Pat Fry has also left the team to join Williams as chief technical officer. The shake-up follows Laurent Rossi leaving his role as CEO of the F1 team last week, with Philippe Krief replacing him. Alpine finished fourth in the Constructors’ Championship last season but lost Fernando Alonso to Aston Martin and test driver Oscar Piastri to McLaren. The French duo of Esteban Ocon and Pierre Gasly have endured a tricky first half of the season, though Ocon did claim a podium in Monaco. Read More F1 Belgian Grand Prix LIVE: Qualifying updates and FP1 lap times at Spa-Francorchamps F1 grid: Starting positions for Belgian Grand Prix Carlos Sainz interview: ‘All of us at Ferrari expected more – we haven’t done the best job’ F1 Belgian Grand Prix LIVE: Qualifying updates and times at Spa-Francorchamps Max Verstappen receives penalty for Belgian Grand Prix What time is qualifying at the Belgian Grand Prix on Friday?

Stores, restaurants and independent entrepreneurs are taking full advantage of the history-making success of the "Barbie" movie to merchandise all kinds of pink products.

The ick is now an undisputed part of not only our dating lexicon, but our

Using existing drugs to treat cervical cancer before standard treatment could lead to a 35% reduction in the risk of relapse or death, a new study suggests. Researchers from the UCL Cancer Institute and UCLH looked into whether a short course of induction chemotherapy (IC), where a drug is used to destroy as many cancer cells as possible, before chemoradiation (CRT), could help with this. Here’s everything you need to know about the findings… What is cervical cancer? According to the NHS website, cervical cancer is a type of cancer found anywhere near the cervix – the opening between the vagina and the womb (uterus), which is also known as the neck of the womb. Most cervical cancers grow very slowly and are caused by an infection from specific types of human papillomavirus (HPV) and mostly affect women under the age of 45. According to Jo’s Cervical Cancer Trust, symptoms include vaginal bleeding that is unusual to you, changes to vaginal discharge, discomfort during sex and pain in your lower back or pelvis. Changes to cells can be spotted by a cervical screening, and then treated before they turn into cancer. There are around 3,200 new cases every year in the UK, with the five-year survival rate being around 70%, according to Cancer Research UK. CRT has been the standard treatment for cervical cancer patients since 1999, but even though there have been overall significant developments in radiation therapy techniques, up to 30% of people experience their cancer coming back. What did the research involve? Over a 10-year period, 500 patients who had been diagnosed with cervical cancer – that was large enough to see without a microscope but hadn’t spread to other parts of the body – took part in the Interlace trial at hospitals in the UK, Mexico, India, Italy and Brazil. Researchers looked into whether a short course of IC before CRT could reduce rates of relapse and death. What results were found? After five years, researchers discovered that 80% of the people who received a combination of chemotherapy and radiotherapy were alive, whilst 73% had not seen their cancer return or spread. A major benefit, according to researchers, is that it can be incorporated into standard of care treatment relatively quickly, because cheap, accessible and already-approved ingredients such as carboplatin and paclitaxel are needed for IC. “Our trial shows that this short course of additional chemotherapy delivered immediately before the standard CRT can reduce the risk of the cancer returning or death by 35%,” said Dr Mary McCormack, lead investigator of the trial from UCL Cancer Institute and UCLH. “This is the biggest improvement in outcome in this disease in over 20 years. “I’m incredibly proud of all the patients who participated in the trial; their contribution has allowed us to gather the evidence needed to improve treatment of cervical cancer patients everywhere. “We couldn’t have done this without the generous support of Cancer Research UK.” Why is the research important? Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: “Timing is everything when you’re treating cancer. The simple act of adding induction chemotherapy to the start of chemoradiation treatment for cervical cancer has delivered remarkable results in this trial. “A growing body of evidence is showing the value of additional rounds of chemotherapy before other treatments like surgery and radiotherapy in several other cancers. “Not only can it reduce the chances of cancer coming back, it can be delivered quickly using drugs already available worldwide. “We’re excited for the improvements this trial could bring to cervical cancer treatment and hope short courses of induction chemotherapy will be rapidly adopted in the clinic.”

Watch the Busby Family as they make a comeback on TLC's 'OutDaughtered' with a Season 9

The Rugby World Cup quarter-finals were absolutely incredible. We're not sure how the semi-finals can

TL;DR: As of August 23, you can get the OMNIA M2+ MagSafe wireless charging station

By Leigh Thomas PARIS France prides itself on taking its food seriously, but many consumers are now tightening

The US Supreme Court ruled Friday that some private businesses can refuse service to same-sex couples for religious reasons, in a...

India is about to make a bold attempt to land on the moon with its

Hailey Bieber has grand plans for her skin-care label, Rhode, aiming to stand out in an increasingly crowded